Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
The Readout

The doomsday theory of biopharma R&D & the lowlights of the long weekend

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Nov. 27, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for November 27, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Dutch health minister won’t cover a Gilead cancer drug…
Dutch health minister won’t cover a Gilead cancer drug due to the cost
The science behind Janet Jackson’s pregnancy at 49
The science behind Janet Jackson’s pregnancy at 49
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
How Biogen got Aduhelm approved, Sanofi’s future in mRNA,…
How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga

Recommended Stories